ANNOUNCEMENT AT LEAST [***] PRIOR TO ITS SCHEDULED
RELEASE. EACH PARTY WILL HAVE THE RIGHT TO EXPEDITIOUSLY REVIEW AND RECOMMEND
CHANGES TO ANY SUCH ANNOUNCEMENT AND, EXCEPT AS OTHERWISE PERMITTED BY ARTICLE
8, THE PARTY WHOSE ANNOUNCEMENT HAS BEEN REVIEWED WILL REMOVE ANY INFORMATION
THE REVIEWING PARTY REASONABLY DEEMS TO BE INAPPROPRIATE FOR DISCLOSURE. THE
CONTENTS OF ANY ANNOUNCEMENT OR SIMILAR PUBLICITY WHICH HAS BEEN REVIEWED,
APPROVED AND RELEASED BY THE REVIEWING PARTY CAN BE RE-RELEASED BY EITHER PARTY
WITHOUT A REQUIREMENT FOR RE-APPROVAL. NOTWITHSTANDING THE FOREGOING AND SUBJECT
TO ARTICLE 8, THE PARTIES AGREE THAT SUCH PUBLIC DISCLOSURES SHALL MINIMIZE THE
DISCLOSURE OF FINANCIAL INFORMATION.
7.1.2
EACH PARTY WILL IMMEDIATELY NOTIFY (AND PROVIDE AS MUCH ADVANCE NOTICE AS
POSSIBLE TO) THE OTHER OF ANY EVENT MATERIALLY RELATED TO PRODUCTS (INCLUDING
ANY REGULATORY APPROVAL) SO THAT THE PARTIES MAY ANALYZE THE NEED TO OR
DESIRABILITY OF PUBLICLY DISCLOSING OR REPORTING SUCH EVENT. NOTWITHSTANDING
SECTION 7.1.1 ABOVE, ANY PRESS RELEASE OR OTHER SIMILAR PUBLIC COMMUNICATION BY
EITHER PARTY RELATED TO A PRODUCT'S EFFICACY OR SAFETY DATA AND/OR RESULTS, WILL
BE SUBMITTED TO THE OTHER PARTY FOR REVIEW AND APPROVAL AT LEAST [***] [***] IN
ADVANCE OF SUCH PROPOSED PUBLIC DISCLOSURE. EXCEPT AS PERMITTED BY ARTICLE 8,
SUCH PUBLIC DISCLOSURES SHALL BE PERMITTED AT THE SOLE DISCRETION OF OMI.
21
SECTION
7.2
PUBLICATION OF RESEARCH RESULTS. DURING THE COLLABORATION TERM, NEITHER PARTY
WILL PUBLISH, PRESENT OR OTHERWISE DISCLOSE TO THE PUBLIC THE RESEARCH RESULTS
EXCLUSIVELY LICENSED TO OMI HEREUNDER OR INFORMATION RELATING TO COLLABORATION
GENE TARGETS, EXCEPT AS SPECIFICALLY APPROVED BY THE R&D COMMITTEE. THE R&D
COMMITTEE WILL AGREE UPON THE FORM AND TIMING OF ANY PUBLICATION OR PRESENTATION
OR OTHER DISCLOSURE (SUCH AS AN ABSTRACT, MANUSCRIPT OR PRESENTATION) TO THE
PUBLIC OF THE RESEARCH RESULTS EXCLUSIVELY LICENSED TO OMI HEREUNDER OR
INFORMATION RELATING TO COLLABORATION GENE TARGETS. FOR CLARIFICATION, THIS
SECTION 7.2 WILL NOT APPLY WITH RESPECT TO THE USE AND DISCLOSURE OF
CONFIDENTIAL INFORMATION AS SPECIFICALLY PROVIDED FOR IN SECTION 7.1 OR ARTICLE
8 (I.E., A DISCLOSURE EXPRESSLY PERMITTED AND MADE IN ACCORDANCE WITH SECTION
7.1 OR ARTICLE 8). AT THE TERMINATION OF THE COLLABORATION TERM AND SOLELY WITH
RESPECT TO SELECTED GENE TARGETS FOR WHICH OMI HAS DESIGNATED A COMPOUND AS A
CLINICAL CANDIDATE, OMI MAY PUBLISH, PRESENT OR OTHERWISE DISCLOSE RESEARCH
RESULTS TO THE PUBLIC AT ITS SOLE DISCRETION SUBJECT TO ARTICLE 8; HOWEVER, OMI
WILL NOTIFY ISIS [***] IN ADVANCE OF THE PUBLICATION.
ARTICLE 8 -
CONFIDENTIALITY
SECTION
8.1
DISCLOSURE AND USE RESTRICTION. EACH PARTY AGREES THAT, FOR SO LONG AS THIS
AGREEMENT IS IN EFFECT AND FOR A PERIOD OF [***] THEREAFTER, A PARTY (THE
"RECEIVING PARTY") RECEIVING CONFIDENTIAL INFORMATION OF THE OTHER PARTY (THE
"DISCLOSING PARTY") WILL (I) MAINTAIN IN CONFIDENCE SUCH CONFIDENTIAL
INFORMATION USING NOT LESS THAN THE EFFORTS SUCH RECEIVING PARTY USES TO
MAINTAIN IN CONFIDENCE OTHER PROPRIETARY INDUSTRIAL INFORMATION OF SIMILAR KIND
AND VALUE, (II) NOT DISCLOSE SUCH CONFIDENTIAL INFORMATION EXCEPT TO THE
RECEIVING PARTY'S EMPLOYEES, OR AFFILIATES OF THE RECEIVING